CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort

OBJECTIVE: Simvastatin is primarily metabolized by CYP3A4. A combined CYP3A4/5 genotype classification, combining the decrease-of-function CYP3A4*22 and the loss-of-function CYP3A5*3, has recently been reported. We aim to determine whether CYP3A4*22 and CYP3A5*3 alleles are associated with increased...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kitzmiller, Joseph P., Luzum, Jasmine A., Baldassarre, Damiano, Krauss, Ronald M., Medina, Marisa W.
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2014
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4160394/
https://ncbi.nlm.nih.gov/pubmed/25051018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0000000000000079
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars